drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Gene-modified cellular immunotherapy consisting of gamma-delta T lymphocytes engineered to express a CD19-specific chimeric antigen receptor; administered by IV infusion to deplete CD19+ B-lineage cells and suppress B cell–mediated autoimmunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gamma-delta T lymphocytes engineered to express a CD19-specific chimeric antigen receptor bind CD19 on B-lineage cells, triggering T-cell activation and cytotoxicity (perforin/granzyme and inflammatory cytokines) to deplete CD19+ B cells and suppress B cell–mediated autoimmunity.
drug_name
UTAA09 (CD19 CAR γδ T cells)
nct_id_drug_ref
NCT06361745